SAN DIEGO, Sept. 20 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the 10th Annual Biotech in Europe Investor Forum to be held September 29-30, 2010 at the Radisson Blu Hotel in Zurich. Although this presentation will not be webcast, investors can access a replay of the Company's recent presentation at the Rodman & Renshaw 12th Annual Healthcare Investment Conference at http://www.wsw.com/webcast/rrshq18/cxm/ or at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium lifestyle medicinals brand platform. The Company's lead product candidates include: (1) Excellagen™ topical gel, for wound care management, which Cardium plans to market launch in the fourth quarter subject to pending FDA 510(k) clearance; and (2) Generx®, a DNA-based angiogenic cardiovascular biologic for patients in international mark
|SOURCE Cardium Therapeutics|
Copyright©2010 PR Newswire.
All rights reserved